RECOTHROM topical hemostat has low rate of anti-product antibody formation and is well-tolerated
RECOTHROM topical hemostat has low rate of anti-product antibody formation and is well-tolerated
ZymoGenetics, Inc., today announced the publication of pooled safety and immunogenicity observations from eight clinical trials of RECOTHROM in the February issue of the Journal of the American College of Surgeons. The authors concluded that RECOTHROM is a well-tolerated topical hemostatic agent in numerous surgical settings and has a low rate of anti-product antibody formation. In the pooled …
Read more on News-Medical-Net
